| 前收市價 | 1.2000 |
| 開市 | 1.2300 |
| 買盤 | 0.2500 |
| 賣出價 | 1.0000 |
| 拍板 | 30.00 |
| 到期日 | 2024-11-15 |
| 今日波幅 | 1.2000 - 1.3500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 11 |
ZacksInsmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Investor's Business DailyThe Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.
Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment succeeded in a final-phase study.
Barrons.comInsmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.
Analysts had said shares could more than double if the trial was a success, or fall by more than half if it failed. The drug brensocatib, treats a condition called bronchiectasis.
